C
인벤테라
0007J0KOSDAQ자연과학 및 공학 연구개발업42.0 / 100
Reference Date: 2026-04-13
Financial Score15.5 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 28.4% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Invenia is a biopharmaceutical company developing the 'Invinity™' polysaccharide-based nanotechnology platform to inhibit protein corona formation, enhance intrabody stability, and enable targeted drug delivery. The company focuses on addressing unmet medical needs through alternative MRI contrast agents and nano-medicines administered via oral or intra-articular injection methods.
Number of Employees
18people
Average Salary
78.2M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 120.074.0Point
PBR
13.92Industry Average 3.820.0Point
3.6x industry avg (risky)
ROE
-45.55Industry Average -32.113.5Point
In line with industry avg
Debt Ratio
3.92Industry Average 7.525.0Point
Lower than industry avg (good)
Trend 3.0 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
1.5 / 3
ROE Trend
0.0 / 4
Detailed News Sentiment
6 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50
- Neutral
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 25,250Won52-week high 35,25052-week low 25,200
1-month return0.0Point
1m -28.37% (strong drop)
Volume trend3.0Point
Volume dry-up
Detailed Disclosure
9 totalPositive 0Neutral 9Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-04-09
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-09
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-09
- Neutral주식등의대량보유상황보고서(약식)2026-04-09
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-09